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Abstract
 
Expression of V(D)J recombinase activity in developing lymphocytes is absolutely required for
initiation of V(D)J recombination at antigen receptor loci. However, little is known about when
during hematopoietic development the V(D)J recombinase is first active, nor is it known what
elements activate the recombinase in multipotent hematopoietic progenitors. Using mice that
express a fluorescent transgenic V(D)J recombination reporter, we show that the V(D)J recom-
binase is active as early as common lymphoid progenitors (CLPs) but not in the upstream pro-
genitors that retain myeloid lineage potential. Evidence of this recombinase activity is detectable
 
in all four progeny lineages (B, T, and NK, and DC), and 
 
rag2
 
 levels are the highest in progenitor
subsets immediately downstream of the CLP. By single cell PCR, we demonstrate that V(D)J
 
rearrangements are detectable at IgH loci in 
 
 
 
5% of splenic natural killer cells. Finally, we show
 
that recombinase activity in CLPs is largely controlled by the E
 
rag
 
 enhancer. As activity of the
 
E
 
rag
 
 enhancer is restricted to the B cell lineage, this provides the first molecular evidence for
establishment of a lineage-specific transcription program in multipotent progenitors.
Key words: B lymphopoiesis • V(D)J recombination • lineage restriction • hematopoiesis • 
stem cell • transcription
 
Introduction
 
Commitment of hematopoietic progenitors to the B or T
lineage is associated with the production of transcription
factors that initiate expression of proteins essential to the B
or T cell fate and repress proteins involved in alternative
fates (1, 2). The V(D)J recombinase is an enzyme complex
 
that is absolutely required for normal B and T cell production
(3, 4). In the absence of recombinase activity, lymphoid devel-
 
opment is abrogated at an early stage resulting in severe
combined immune deficiency. Therefore, characterizing
developmental regulation of V(D)J recombinase activity in
multipotential hematopoietic progenitors is fundamental to
understanding progression to the B and T cell lineages.
The V(D)J recombinase is composed of recombinase-
activating gene (RAG)1 and RAG2 as well as the DNA
repair proteins Ku70 and Ku80, DNA-PKcs, DNA ligase
IV, XRCC4, and Artemis (5–14). RAG1 and RAG2 are
tightly regulated: 
 
rag
 
 expression is limited to specific devel-
opmental subsets of B and T lymphocytes (10, 11, 15–17),
and RAG2 protein must be resynthesized and relocalized
to the nucleus with every cell cycle (18–20). Like RAG2,
nonhomologous end joining activity may also be regulated
by phosphorylation (21). Thus, 
 
rag
 
 transcription, although
required for recombinase function, is not necessarily a defin-
itive indicator of recombinase activity (15, 22, 23).
 
rag
 
 expression is differently regulated in B versus T lineage
 
progenitors, and the cis-acting elements that control both
development and lineage specificity are just beginning to
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be resolved. The 10-kb region upstream of 
 
rag2
 
 is suffi-
cient for both complementing lymphocyte development
 
in 
 
rag2
 
 
 
/
 
 
 
 animals (24) and controlling normal expression
of 
 
rag1
 
 and 
 
rag2
 
 in B and T lineage progenitors (17). At
least two enhancers have been identified within this locus,
 
one at 
 
 
 
8 kb and a second at 
 
 
 
22 kb upstream of 
 
rag2
 
(25, 26). The latter of these, identified as E
 
rag
 
, is particu-
larly interesting because it exhibits B lineage specificity.
Mice lacking E
 
rag
 
 have severely reduced expression of 
 
rag1
 
and 
 
rag2
 
 in B lineage progenitors leading to a partial block
in B cell development, whereas T cell development re-
mains unaffected.
Both B and T lineage progenitors can be derived from
the same multipotent CLP (27, 28), and it remains un-
known whether E
 
rag
 
 begins to exert influence only in cells
committed to the B lineage. Interestingly, even though
bone marrow CLPs retain the ability to produce both B
and T cells, these multipotential progenitors may not con-
tribute to each lineage equally. Specifically, 
 
ikaros
 
 knockout
mice lack CLPs but are nonetheless able to generate near
normal frequencies of early thymic T lineage progenitors
(ETPs) (29). These and additional data suggest that CLPs
are early B lineage progenitors, whereas ETPs are early T
lineage progenitors. However, the molecular basis underly-
ing this observation remains unknown.
 
In addition to T and B cells, CLPs can give rise to NK cells
and DCs in vivo. The close developmental relationship be-
tween these cells is further supported by observations that
 
lin
 
 
 
ckit
 
lo
 
 progenitors can produce either CD19
 
 
 
 B cells or
DX5
 
 
 
 NK cells (30), B lineage precursors share developmen-
tal markers with DC precursors (28), and CD19
 
 
 
 B lympho-
cytes cultured in vitro can give rise to DEC205
 
 
 
CD11c
 
 
 
cells (31). Despite these developmental relationships and the
fact that IgH recombination events are detectable in CLPs
(29), recombinase expression is widely considered to be re-
stricted to lineage-committed B and T progenitors.
To investigate expression and control of recombinase ac-
tivity in multipotential hematopoietic progenitors and their
Figure 1. (A) The transgenic
H2-SVEX substrate contains
VEX (white rectangle) driven
by the murine H2K promoter
(black rectangle). VEX within
the substrate is initially in the anti-
sense  orientation and is flanked
by V(D)J recombination signal
sequences (triangles) which direct
inversional recombination. Prim-
ers used to discriminate H2-SVEX
before and after rearrangement
are indicated (2011, 200, 586,
and 2165; as described in Materials
and Methods). (B) Splenocytes
from SB110 and SB88 H2-
SVEX animals were stained with
antibodies to detect CD19 
IgM  B cells, CD3  T cells,
CD11b CD3 CD19 NK1.1 
myeloid cells, or Gr-1 
CD19 CD3 NK1.1  granulo-
cytes and subsequently examined
for VEX expression. The percent-
age of VEX  cells in the gate is
given, and outliers are shown.
(C) H2-SVEX recombination
depends on RAG1. B220  B cells
in the bone marrow were exam-
ined for VEX expression in
H2-SVEX SB110, H2-SVEX
RAG1 / , RAG / , and non-
transgenic C57BL/6 control
mice. The percentage of VEX 
cells in the gate is given. H2-
SVEX RAG1 /  mice were
identified by PCR analysis of the
SVEX cassette as depicted in A
and Fig. 2 A. Identical results
were obtained with SB88 H2-
SVEX RAG1 /  mice (not de-
picted). The data presented are
representative of six independent
experiments. 
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immediate downstream progeny in vivo, we developed a
flow cytometric assay in which V(D)J recombination of a
transgenic substrate is indicated by VEX-GFP fluorescence.
Within specific developmental subsets of lymphocytes, we
can distinguish individual cells that begin to express the re-
combinase. This approach, which has not previously been
possible in primary cells, enables us to examine in vivo the
developmental onset of expression of V(D)J recombinase
activity and the factors that regulate it. Moreover, once the
substrate is recombined VEX continues to be expressed. Be-
cause VEX acts a permanent marker of cells that have, or
had, recombinase activity, we also have the opportunity to
 
evaluate the contribution of recombinase
 
 
 
 lymphoid pro-
genitors to the B, T, NK, and DC lineages.
 
Materials and Methods
 
Mice.
 
C57BL/6 and RAG1
 
 
 
/
 
 
 
 (C57BL/6 background) mice
 
were obtained from the Jackson Laboratories. E
 
rag
 
 
 
/
 
 
 
 mice were
provided by Mark Schlissel (University of California, Berkeley,
CA) (26). RAG2 GFP NG BAC mice (FVBN) provided by
Michel Nussenzweig (The Rockefeller University, New York,
NY) (17) were backcrossed to C57BL/6 in our laboratory for 12
generations. All mice were treated humanely in accordance with
federal and state government guidelines and UMMS institutional
animal committees.
 
Construction of H2-SVEX Transgenic Mice.
 
The H2-SVEX
transgene was constructed by placing the RSS-VEX-RSS frag-
ment (Fig. 1 A) into the H2K (HIL) transgenic vector using a
unique NotI restriction site located between the H2 promoter
and the H2 exon fragment. The H2K cassette vector expresses
genes under the control of the H2K promoter/enhancer and
Moloney MuLV enhancer/poly(A), typically at high levels in
HSC and all hematolymphoid cells (32–35). Heterologous pro-
moter activation has been shown to be sufficient for directing re-
arrangement of chromosomal recombination substrates (36).
Transgenic mice were made at the UMMS transgenic facility us-
ing standard procedures. From the injected C57BL/6 embryos,
13 of 136 mice were positive for the transgene as analyzed by
PCR. Of these potential founders, six expressed VEX in periph-
eral white blood cells and four such mice were used to establish
permanent transgenic lines: SB68, SB88, SB110, and SB114.
VEX is from MFG-hu-VEX-2 (37–39). The 
 
recombination
signal sequence (
 
RSS) fragments contain consensus RSS and 16
bp from the murine DFL16.1 coding region (12-RSS) or 17 bp
from the murine JH1 coding region (23-RSS) (40).
 
Cell Sorting and Flow Cytometry.
 
Freshly isolated cells were
 
resuspended to 3 
 
 
 
 10
 
7 
 
cells/ml in staining media containing
biotin-, flavin-, and phenol red–deficient RPMI 1640 (Irvine
Scientific), 10 mM Hepes, pH 7.2, 0.02% sodium azide, 1 mM
EDTA, and 3% newborn calf serum and treated with 2.4G2 Fc
block for 10 min on ice. Cells were incubated with primary anti-
bodies for 20 min, then washed three times, incubated with
streptavidin reagents for 15 min, and then washed three more
 
times. After the final wash, samples were resuspended in 1 
 
 
 
g/ml
propidium iodide to exclude dead cells. Primary antibodies in-
cluded AA4.1 biotin or APC, B220 APC or Cy5PE or FITC,
BP-1 biotin (6C3), CD3 Cy5PE or PE, CD4 Cy5PE or PE,
CD8 APC or Cy5PE or PE, CD11b APC (M1/70), CD19
Cy5PE or FITC, CD24 Cascade blue, Alexa 594 or FITC (30-
F1), CD43 PE, CD122 biotin or PE, c-kit PE, DX5 biotin or
FITC, Ly6C biotin or FITC, Gr-1 PE (Ly6G; RB6–8C5), IgM
biotin or FITC, IL-7R PE (SB/14 or A7R34), Ly49G APC, and
NK1.1 biotin or FITC. Secondary reagents were SA-Cy5PE,
SA-Alexa 594, SA-Cy7PE or SA-APC. Antibodies were pur-
chased from BD Biosciences, eBioscience, Southern Biotechnol-
ogy Associates, Inc., or CALTAG and purified and conjugated
using established procedures (37). Flow cytometry was performed
on a 3 laser, 7 detector DIVA FACSVantage or a 3 laser 9 detec-
tor LSRII (Becton Dickinson). VEX was detected using 407 nm
excitation and a 510-nm (10-nm bandpass) filter (37). Data were
analyzed with FlowJo software (Tree Star), and all flow cytomet-
ric data is presented as 5% contour plots.
 
DNA Isolation and PCR.
 
Genomic DNA was isolated with
the QIAGEN DNeasy kit according to the manufacturer’s in-
structions. PCR amplification was performed with 10 
 
 
 
l DNA in
25 
 
 
 
l total volume with 1.6 
 
 
 
M dNTP (dATP 
 
 
 
 dTTP 
 
 
 
dCTP 
 
 
 
 dGTP), 2.5 U Taq, 4 mM MgCl
 
2
 
, 1
 
 
 
 buffer A (Fisher
Scientific), and 4 
 
 
 
M of each primer. Primers were 2011 (5
 
 
 
),
TAAAGTCCACGCAGCCCGCAGA; 2165 (3
 
 
 
), GGTG-
GAGAAGGGGCGGAGGGTC; 586 (5
 
 
 
), GCCCCGTGCT-
GCTGCCCGACA; and 200 (3
 
 
 
), CGCCGTAGCTGAAG-
GTGGTC. Primers were used in the following combinations
(refer to Fig. 1 A for primer location): H2-SVEX transgene, 2011
and 2165; coding joints (CJs), 200 and 2011; and signal joints
(SJs), 586 and 2165. PCR conditions consisted of 30 cycles unless
otherwise indicated (94
 
 
 
C for 1 min, 68
 
 
 
C for 30 s, and 72
 
 
 
C for
1 min) in an Eppendorf Mastercycler. PCR products were visual-
ized with ethidium bromine on a 1.5% agarose gel in TBE buffer.
Single cell PCR analysis for D-JH rearrangements in NK cells
was performed as described previously (23).
 
Online Supplemental Material.
 
Fig. S1 shows lymphocyte sub-
sets in the four independent H2-SVEX founder lines. Fig. S2
characterizes VEX expression in NK cells from C57BL/6 and
 
RAG1
 
 
 
/
 
 
 
 mice. Table S1 reports the sequence of CJs and SJs
 
from independent H2-SVEX rearrangements. Supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20031800/DC1.
 
Results
 
The H2-SVEX Transgenic Recombination Substrate.
 
To
detect the developmental onset of V(D)J recombinase ac-
 
tivity, we developed a FACS
 
®
 
 reporter gene system in
which V(D)J recombination of a transgenic substrate is in-
dicated by VEX fluorescence. VEX is a variant of GFP
(37). The V(D)J recombination substrate H2-SVEX ex-
presses VEX as a consequence of V(D)J recombination. As
shown in Fig. 1 A, the VEX gene is initially in the anti-
sense orientation and is flanked by V(D)J RSSs. RSSs in
this orientation mediate inversion such that after recombi-
nation VEX is in the correct orientation for expression.
 
Cells that undergo V(D)J recombination are VEX
 
 
 
; these
cells are easily detected and quantified by FACS
 
®
 
.
We examined VEX expression in four independent H2-
SVEX transgenic lines, SB68, SB88, SB110, and SB114.
All four transgenic lines have the same frequency and num-
ber of cells within subpopulations of hematopoietic and
lymphoid cells compared with wild-type, indicating that
 
cells that express VEX are not at a developmental or
homeostatic disadvantage (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20031800/DC1). 
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Specificity and Efficiency of the H2-SVEX Recombination
Substrate. The H2-SVEX construct is driven by an active
H2K (murine MHC class I) promoter/MoMLV enhancer
that enables robust transgene expression and, presumably,
accessibility in all hematopoietic cells (32, 33, 35). Charac-
terization of VEX expression in primary lymphoid tissue
demonstrates the specificity and efficiency of the H2-SVEX
recombination substrate. Within the B lymphocyte lineage,
94% of immature B220 IgM CD24hiLy6C DX5  bone
marrow B cells (23) and 84–86% of CD19 IgM  splenic B
cells (Fig. 1 B) are VEX , indicating efficient recombina-
tion of the substrate in both the SB110 and SB88 H2-SVEX
lines. VEX expression is also high among splenic T lympho-
cytes since 91–93% of CD3  T cells are VEX . By contrast,
0.5% of splenic myeloid cells and 0.3–0.5% of granulocytes
are VEX , suggesting that H2-SVEX is not rearranged in
nonlymphoid lineages. Importantly, Fig. 1 B shows that the
percentage of VEX  B and T cells is nearly identical be-
tween the two independent founder lines depicted (SB88
and SB110), indicating position-independent regulation of
recombination.
To demonstrate directly that H2-SVEX undergoes V(D)J
recombination, we bred H2-SVEX mice to RAG1 / 
mice. H2-SVEX recombination in both SB110 and SB88
transgenic B220  bone marrow cells is abolished in the ab-
sence of RAG1 as the frequency of detectable VEX  cells is
diminished from 66% in wild-type H2-SVEX to 1.3% in
H2-SVEX RAG1 /  animals, comparable to background
fluorescence detected in C57BL/6 and RAG1 /  nontrans-
genic controls (Fig. 1 C and not depicted).
Together, these data demonstrate that H2-SVEX rear-
rangement (1) is restricted to the lymphoid lineages, (2) re-
combines efficiently as a V(D)J recombination substrate,
with frequencies of rearrangement approaching 90% within
splenic lymphocytes, and (3) completely depends on
RAG1 expression.
H2-SVEX Recombination Has Expected Molecular Charac-
teristics of V(D)J Recombination and Is Accurately Reflected by
VEX Expression. We examined by direct molecular anal-
ysis whether CJs and SJs, characteristic V(D)J recombina-
tion products (Fig. 1 A), are detectable after H2-SVEX
recombination. The gels in Fig. 2 A depict PCR am-
plification of transgene-specific CJ and SJ recombination
products (first and second rows), the transgene itself inde-
pendent of recombination (third row) and, as a loading and
PCR control, endogenous H2K (fourth row) in H2-SVEX
transgenic or C57BL/6 nontransgenic controls. The H2-
SVEX–specific CJs and SJs are detectable in splenocytes
from two H2-SVEX founder lines, SB88 (Fig. 2 A, lane 2)
and SB110 (lane 7), but not C57BL/6 (lane 1). Sequencing
of recombined H2-SVEX products from primary lympho-
cytes confirms that the transgene undergoes multiple, inde-
pendent rearrangements that produce highly variable CJs
(all 12 joints cloned were unique) and relatively conserved
SJs (8 out of 12 joints cloned were perfect; Table S1,
available at http://www.jem.org/cgi/content/full/jem.
20031800/DC1). Neither CJs nor SJs are detectable in
SB88 brain (Fig. 2 A, lane 4), and CJ products are only
very weakly detectable in SB110 kidney (lane 6) relative to
C57BL/6 (lanes 3 and 5). The latter is likely due to low
levels of lymphocyte contamination within this highly vas-
cularized organ, since we can readily amplify rearranged
TCR genes from kidney (not depicted). Moreover, CJ for-
mation is readily detectable in sorted VEX  but not VEX 
Figure 2. (A) PCR analysis of H2-SVEX V(D)J recom-
bination. H2-SVEX recombination products were examined
in two different transgenic lines, SB88 (left panel) or
SB110 (right panel), which express or lack RAG as indicated.
Nontransgenic C57BL/6 animals are presented as a control.
Primers specific to the transgene were used to detect the
recombination products CJs and SJs in the indicated tissues.
Primers that bind within the murine H2K gene were used
to amplify the 1-kb SVEX cassette in transgenic mice
(independent of recombination; labeled H2-SVEX in the
figure) or to amplify a distinct 250-bp PCR product in
both transgenic and wild-type mice (labeled endogenous
H2K) derived from the endogenous H2K gene. Amplifi-
cation of endogenous H2K serves as a positive control
confirming the presence of template DNA. (B) Semiquan-
titative PCR analysis of H2-SVEX recombination. SB88
H2-SVEX bone marrow was FACS® sorted into VEX 
and VEX  populations. DNA from an equivalent number
of cells was subject to PCR analysis for H2-SVEX transgene-
specific CJs, the H2-SVEX transgene, and endogenous
H2K. The PCR conditions were designed to give linear
amplification for CJs, and cell cycle number is indicated.
The data are representative of two to five experiments using
cells from independent sorts.Borghesi et al. 495
BM cells from SB88 H2-SVEX transgenics even after 36
cycles of amplification (Fig. 2 B). These observations indi-
cate that FACS® detection of VEX accurately reflects
V(D)J recombination of the H2-SVEX transgene and pro-
vides strong support for the sensitivity of this GFP-based
reporter construct to reflect in vivo recombination. By
contrast, neither CJs nor SJs are detectable in any of three
independent H2-SVEX RAG1 /  mice (Fig. 2 A, lanes
8–10), confirming that H2-SVEX recombination depends
on RAG activity and, hence, the V(D)J recombinase.
Expression of V(D)J Recombinase Activity in Early Hemato-
poietic Cells. We have demonstrated that V(D)J recombi-
nase activity is detectable in the earliest B and T lineage
progenitors before IgH (and TCR) recombination (23).
One of the major implications of this result is that the re-
combinase may be expressed even before B lineage com-
mitment. To explore this possibility, we examined VEX
expression within the lin IL-7R  AA4.1 Sca-1lo subset
of bone marrow, which contains hematopoietic precursors
that retain lymphoid (B, T, NK, and DC), but not myeloid
developmental potential (27, 28), and are designated as
common lymphoid progenitors or CLPs. VEX expression
is readily detectable in 30–45% of CLPs (Fig. 3 A and not
depicted; see also Fig. 6).
We then examined recombinase activity in earlier he-
matopoietic progenitor subsets that retain the capacity for
self-renewal. Recombinase activity is not detectable in
lin ckithiCD27  progenitors (Fig. 3 B, left). However, VEX
expression is detectable in a minor subset (1.7%) of
ckithiCD27  progenitors, cells that include the lymphoid-
restricted early lymphoid progenitor (41), as well as a subset
(15%) of ckitintCD27  progenitors (Fig. 3 B, middle and
right), cells that include the CLP (27). Together these data
suggest that the V(D)J recombinase is first active at low levels
in hematopoietic progenitors after loss of myeloid develop-
mental potential, and recombinase activity increases through-
out the earliest stages of B lymphocyte development (23).
V(D)J Recombinase Activity in the Natural Killer Cell Lin-
eage. In addition to B and T lymphocytes, the CLP gives
rise to NK and DC, and it is possible that some VEX 
Figure 3. V(D)J recombinase activity in multipotent
hematopoietic progenitors. (A) V(D)J recombinase activity
in CLPs. The lin  subset (B220, CD11b, GR-1, Ter119,
CD3) of bone marrow obtained from SB88 H2-SVEX
transgenic or C57BL/6 control mice was examined for
VEX expression in IL-7R  AA4.1 Sca-1lo/  cells. (B) The
lin  subset of bone marrow obtained from SB110 H2-
SVEX transgenic or C57BL/6 control mice was examined
for VEX expression as a function of c-kit and CD27.
The data are representative of two to five independent
experiments.Erag Controls Recombinase Activity in CLPs 496
CLPs may give rise to these two lineages. Because VEX
permanently marks cells that have expressed the V(D)J re-
combinase, we had the opportunity to examine whether
some NK and DC have a history of recombinase activity.
We first examined VEX in NK precursors (pNK; CD122 
CD4 CD8 CD90 DX5 ) (42, 43). Approximately 60%
of pNK from H2-SVEX mice express VEX versus 0% from
control B6 (Fig. 4 A, right). We also examined expression
of rag2 transcription in this subset using the NG RAG2
transgenic reporter line in which GFP replaces the major
Figure 4. Detection of V(D)J recombinase activity in natural killer cells. (A) The
CD4 CD8 CD90  subset of bone marrow was examined for CD122 and DX5 or NK1.1
expression in control B6 (top) or SB110 H2-SVEX transgenic mice (bottom). Immature
CD122 DX5  NK1.1  pNK cells (gated population in left and middle) were subse-
quently analyzed for VEX expression (right). (B) CD122 NK1.1  cells lacking CD3,
CD4, CD8, and CD19 were examined for VEX expression in bone marrow (left) or
spleen (right) obtained from SB88 H2-SVEX transgenic (top) or control B6 mice (bottom).
Identical results were obtained using SB110 H2-SVEX transgenic mice (not depicted).
(C) Bone marrow CD3 CD4 CD8 CD122 NK1.1 DX5  pNK (top) and CD3 
CD4 CD8 CD122 NK1.1 CD3 CD19  NK (bottom) were examined for GFP expres-
sion in RAG2 GFP NG transgenic (left) or control B6 mice (right). The percentage of cells
in each gate is given. (D) NK1.1 DX5 CD19 CD3 CD4 CD8  spleen cells were sorted
from C57BL/6 or   -TCR / mice were analyzed by PCR for D-JH joins. PCR analysis
of bulk sorted cells is depicted in the gel on the top. SPL refers to total splenic cells. Two
cells lines with known rearrangement patterns were used as controls. The AMLV-trans-
formed cell line A12 is derived from a RAG1 /  mouse and therefore retains germline Ig
configuration (61). The AMLV-transformed “DJH fixed” 300–35 line bears a D-JH1 rear-
rangement (62). D-JH4 was not examined. By PCR analysis of single, sorted NK cells from
C57BL/6 mice, we determined that the frequency of splenic NK that harbor D-JH rear-
rangements was 4.8% (3 D-JH
  cells out of 62 NK cells analyzed) as indicated on the bot-
tom. The data in A–C are representative of two to five independent experiments. The data
in D are representative of at least two experiments using independently sorted cells.Borghesi et al. 497
exon of RAG2 (17). The pNK population from these re-
porter mice had high levels of GFP expression (Fig. 4 C,
top, third row, left panel), indicative of RAG2 transcrip-
tion, supporting the idea that the pNK may have (or may
have had) an active V(D)J recombinase.
Examination of more mature NK cells confirms that NK
cells display evidence of recombinase activity. Within the
CD3 CD8 CD19  subset, VEX expression in CD122 
NK1.1  NK cells is readily detectable in both bone mar-
row and spleen (Fig. 4 B). Decreased expression of VEX in
mature versus precursor NK cells may reflect down-regula-
tion of reporter transgene expression with progression to
this particular lineage or may be due to preferential selec-
tion of NK cells that express little or no recombinase activ-
ity. VEX is also readily detectable in cells bearing the NK
cell–specific Ly49G receptor (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20031800/DC1), and
as with the other lymphocytes, recombination of H2-
SVEX in NK cells depends on the presence of RAG1
(Fig. S1). We also examined rag2 expression in mature
NK cells and found that GFP is detectable only within a
moderate percentage (11–25%) of NK1.1  bone marrow
and spleen cells (Fig. 4 C, bottom left) and is quite dull
compared with expression in pNK (compare Fig. 4 C, top
and bottom). These data suggest that rag2 is likely to be
expressed and active only at a very early stage of NK de-
velopment rather than during later maturation stages in
the bone marrow.
IgH Recombination in NK Cells. To demonstrate that
the V(D)J recombinase can recombine antigen receptor
loci in NK cells, we took advantage of observations that
IgH recombination events can be detected in T cells and
thus are not B lineage restricted (44, 45). Specifically, we
examined whether D-JH recombination events could also
be found in NK cells. As shown in Fig. 4 D, sorted NK
cells from C57BL/6 mice have readily detectable D-JH
joins, suggesting that the V(D)J recombinase is active at en-
dogenous loci in NK cells. Moreover, D-JH joins are also
detectable in NK cells from TCR   /  animals, demon-
strating that this result is not due to contamination by ei-
ther NK T cells or classical T cells, many of which harbor
D-JH joins. To obtain a quantitative estimate of the fre-
quency of NK cells that possess rearrangement events, we
examined the frequency of D-JH joins by single cell PCR
analysis. We found that 3/62 ( 5%) splenic NK cells have
detectable D-JH joins. Together, these data indicate that the
V(D)J recombinase is active at some point in the develop-
mental history of NK cells and can complete the DH to JH
joining step.
V(D)J Recombinase Activity in the DC Lineage. We ex-
tended our observations to examine recombinase expres-
sion in the DC lineage, which includes cells that also arise
from the CLP. We found that 12% of DC progenitors (28)
from H2-SVEX animals express VEX versus 0% of control
B6 animals (Fig. 5 A). DC progenitors isolated from RAG2
GFP transgenic mice also express GFP (17). Splenic DCs
can be resolved into two populations based on phenotype,
CD8 Mac-1  and CD8 Mac-1  (46–48). VEX is detect-
able in both DC populations as 6% of CD8 Mac-1  DCs
and 5.2% of CD8 Mac-1  DCs from H2-SVEX mice are
VEX  versus  2% from B6 controls (Fig. 5 B, bottom).
Thus, VEX expression, indicative of V(D)J recombinase
activity, is detectable in both NK and DC lineages.
B Lineage–specific Regulation of V(D)J Recombinase Activity
in Early Hematopoietic Cells. rag expression is controlled by
different transacting factors in B versus T cells; yet our data
show that the V(D)J recombinase is active in 30–45% of
CLPs, cells which retain the potential to produce both B
and T cells. Therefore, we wondered whether lineage-spe-
cific regulation of recombination would be evident in
CLPs. The Erag enhancer element, located  22 kb up-
stream of the rag2 gene, profoundly influences expression
of both rag1 and rag2 in a B lineage–specific manner (26).
Erag /  animals have a twofold reduction in rag2 transcripts
Figure 5. Detection of V(D)J recombinase activity in DCs. (A) VEX
expression was examined in AA4.1 B220 CD4 CD24  bone marrow
progenitors from SB110 H2-SVEX transgenic (left) or B6 control mice
(right). (B) Splenic DCs were enriched by collagenase digestion and
Nycodenz gradient centrifugation of tissue obtained from SB110 H2-SVEX
transgenic (left) or C57BL/6 control mice (right). The CD11c I-A  subset
was examined for expression of CD8, Mac-1, and VEX. The percentage
of cells in each gate is given. The data are representative of at least five (A)
or two (B) independent experiments, and identical results were obtained
with SB88 H2-SVEX transgenics (not depicted).Erag Controls Recombinase Activity in CLPs 498
Figure 6. Regulation of V(D)J recombinase activity in multipotential lineage progenitors. (A) Bone marrow from SB110 H2-SVEX animals
that were Erag / , Erag / , or Erag /  was stained for IL-7R  AA4.1 Sca-1lo/ lin  CLPs (top), and cells within the CLP gate were examined for
VEX expression (bottom). Identical results were obtained when wild-type SB110 and SB88 H2-SVEX mice were compared (not depicted). (B)
VEX expression was analyzed in B220 CD43 DX5 Ly6C IgM  CD19 CD24  pro-B cells (bottom row). (C) VEX expression was analyzed in
CD3 CD19  splenic T cells. The percentage of each population within the gate is given. The data are representative of two to five independent
experiments.Borghesi et al. 499
and a 10-fold reduction in rag1 transcripts in pro- and pre-B
cells, whereas the T lineage remains unaffected. Therefore,
we examined whether Erag was important for controlling
recombinase activity in CLPs.
Fig. 6 A (top) depicts identification of CLPs (lin 
IL7R  AA4.1 Sca-1lo) in nontransgenic wild-type ani-
mals and in three transgenic mice: H2-SVEX Erag / , H2-
SVEX Erag / , and H2-SVEX Erag / . The percentage of
AA4.1 Sca-1lo CLP cells was similar across all four mice,
ranging from 17–26% of lin IL7R   cells (Fig. 6 A, top).
However, whereas 45% of CLPs from H2-SVEX transgenic
Erag /  or Erag /  siblings express VEX (Fig. 6 A, bottom),
the Erag /  mice had a dramatic (fivefold) reduction in VEX
expression (9%; Fig. 6 A, bottom, far right). The decline in
recombinase activity in the CLP suggests that B cell–specific
regulation of rag gene expression already exists even at this
early stage of hematopoietic development.
VEX expression is also dramatically reduced in pro-B
subsets from H2-SVEX Erag /  transgenics. The percent-
age of VEX expression in pre-pro-B cells is reduced from
17% in H2-SVEX Erag /  to 6% in Erag /  and to 3.2% in
Erag /  animals (not depicted), a fivefold reduction com-
parable to the magnitude of decrease observed in CLPs.
VEX expression in later pro-B cells is reduced from  90%
in H2-SVEX Erag /  and Erag /  mice to 24% in Erag / 
(Fig. 6 B). In contrast, VEX expression in CD3  T cells is
only modestly reduced (1.2-fold) from 92% H2-SVEX
Erag /  and in Erag /  to 70% in Erag /  animals (Fig. 6
C), confirming that V(D)J recombinase activity in the B
but not T lineage strongly depends on the Erag element.
Discussion
To examine developmental control of V(D)J recombi-
nase activity in single, multipotent hematopoietic progeni-
tors, we developed mice that express the fluorescent V(D)J
recombination substrate H2-SVEX. Once recombined, the
fluorescent substrate is permanently expressed and provides
a useful marker of the developmental history of lympho-
cytes. We use this marker to show that V(D)J recombinase
is active as early as the CLP stage of hematopoietic of de-
velopment, and evidence of this activity is detectable in all
four potential progeny lineages: B, T, NK, and DC. By
single cell PCR, we also demonstrate the presence of D-JH
rearrangements in 4.8% of splenic NK cells. We take ad-
vantage of the sensitivity of H2-SVEX to characterize reg-
ulation of V(D)J recombinase expression in CLPs. We
demonstrate that recombinase activity in this multipotent
population depends on the B lineage enhancer of rag ex-
pression, Erag. This surprising result demonstrates that lin-
eage-specific regulation of rag is already established in this
multipotent progenitor and suggests one mechanism un-
derlying recent observations that the CLP may be biased
toward a B rather than T lineage fate.
V(D)J Recombinase Activity in the CLP. Detection of
V(D)J recombinase activity as early as the CLP stage of he-
matopoietic development extends previous findings that
RAG is expressed not only in progenitors that retain the
capacity to produce B lymphocytes and NK cells (41) but
also in fraction A1 DC precursors (17). These results were
unexpected because recombinase expression was previously
considered restricted to committed B and T cell progeni-
tors. Initiation of V(D)J recombinase expression in CLPs
before progression to the B or T lymphocyte lineage is
consistent with evidence that hematopoietic development
can be very plastic. For example, in pax5 /  mice (49)
B220  bone marrow cells bearing D-JH rearrangements and
previously considered restricted to the B lineage retain the
capacity to give rise to nearly all other blood cells. Even the
classically defined CLP (lin IL-7R Thy-1 Sca-1loc-kitlo)
that produces B, T, and NK cells has latent myeloid poten-
tial that is induced by ectopic expression of IL-2 and GM-
CSF receptors (50).
V(D)J Recombinase Activity in NK Cells. Our analysis of
NK and DC cells indicates that V(D)J recombinase activity
in the lymphoid compartment is not restricted to the B or
T lineage (Figs. 4 and 5). The intriguing possibility that the
V(D)J recombinase operates in cells other than B and T
progenitors finds additional support in observations that (1)
rag1 transcription is detectable in c-kithiSca-1hiCD27  pro-
genitors that give rise to both lymphocytes and NK cells
(41), (2) incomplete TCR-  rearrangements are detectable
at low levels in some murine NK cells (51), and (3) D-JH
rearrangements are detectable in a subset of murine plasma-
cytoid and thymic DCs (52). Whether the V(D)J recombi-
nase recombines loci other than IgH (Fig. 4 D) and TCR
in the NK lineage remains unknown.
Expression of recombinase activity and, hence, D-JH rear-
rangements in NK may simply be a developmental relic
stemming from recombinase activity in the CLP. The re-
combinase may be expressed in CLPs that have not yet com-
mitted to a specific lymphoid lineage fate (that is, B, T, or
NK, or DC) and may be repressed in more committed NK
cell or DC progenitors. High expression of the RAG2 GFP
transgenic reporter in pNKs but not in later stages of NK de-
velopment (Fig. 4 C) indicates that this repression occurs af-
ter the pNK stage. Moreover, our observation that pNK de-
rived from Erag /  mice have normal levels of VEX
expression (not depicted) even though recombinase activity
in the CLP is significantly decreased (Fig. 6), suggests that
V(D)J recombination could take place during the earliest
stages of NK cell development. Numerous malignancies in-
volving both NK leukemias and lymphomas have been iden-
tified (53–55). Because V(D)J recombination is associated
with chromosomal transposition in vitro (56) and in vivo
(57) as well as chromosomal translocations (58), our observa-
tions raise the possibility that recombinase expression in pNK
cells may contribute to some of these forms of oncogenesis.
Regulation of V(D)J Recombinase Activity in Multipotent He-
matopoietic Progenitors. Given our observation that a pro-
portion of CLPs from H2-SVEX mice express the recom-
binase, we examined whether lineage-specific regulation of
recombination would be evident at this early stage of he-
matopoietic development. The Erag enhancer controls ragErag Controls Recombinase Activity in CLPs 500
expression in B but not T precursors (26). Surprisingly, we
found that Erag also controls recombinase activity in CLPs
as deletion of this enhancer reduced VEX from 45% in
wild-type mice to 8.7% in the Erag /  mice (Fig. 6). Thus,
the B lineage–specific control exerted by the Erag enhancer
is apparent even in multipotential progenitors. These ob-
servations predict that the CLP, or the upstream (as yet un-
characterized) pre-CLP (59), is the target of inductive sig-
nals required for rag expression (60).
The observation that the Erag enhancer influences re-
combinase activity in CLPs has implications for our under-
standing of hematopoietic cell development. Initial models
predicted that CLPs from unmanipulated mice have an
equal chance of adopting a B cell or a T cell fate in vivo
(27, 28). However, a recent report shows that ikaros knock-
out mice lacking CLPs are nonetheless able to generate
near normal frequencies of early thymic T lineage progeni-
tors (29), suggesting that CLPs are early B lineage progeni-
tors that do not contribute significantly to thymic T cell
development despite a residual T lineage potential. Our
data are consistent with this hypothesis and provide the first
molecular evidence supporting the idea that the BM CLP
may have a default B cell fate in vivo.
In conclusion, the broad utility of H2-SVEX recombi-
nation substrate lies in the fact that it (1) sensitively quanti-
fies recombinase activity in vivo, (2) enables analysis at the
single cell level, supporting characterization even of very
rare progenitor populations, and (3) can be assayed simulta-
neous with other GFP transgenic reporters. As one exam-
ple, we successfully quantified recombinase activity in
CLPs (Fig. 3 A), a progenitor population representing
 0.1% of total bone marrow cells (28), and characterized
the role of the Erag enhancer in this population. Our ap-
proach is broadly generalizable since H2-SVEX mice can
be readily used in combination with other genetically mu-
tated strains that affect B and T lymphocyte development.
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